Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Tailoring the Therapy to the Cancer

A single receptor molecule can perform different functions in different cancer types, thereby complicating approaches to therapy. This was the key finding of a study recently published in the British Journal of Cancer (BJC)*.

The study compared the functionality of the HER2/neu receptor in the cancer cells of breast and ovarian cancer tissue. Supported by the Austrian Science Fund FWF, the team of scientists involved have shown that the cellular process regulated by this receptor vary greatly between different cancer types. As HER2/neu is the target of successful breast cancer therapy, this result is of major significance for the treatment of ovarian cancer.

Breast and ovarian cancers can both be hereditary, can both be traced back to the same genetic defect and consequently can both possess a large number of HER2/neu receptors. Why therefore do both cancer types not react in the same way when this receptor is blocked? An approach that has proved to be the biggest success of the past 20 years in the treatment of breast cancer has proved unsuccessful in therapies for ovarian cancer. Dr. Dietmar Pils, a member of the laboratory headed by Prof. Michael Krainer, an oncologist at the Department of Internal Medicine I, Medical University of Vienna, has achieved a major breakthrough in finding an answer to this puzzling question.

One Receptor. Two Effects.

The team compared tissue samples from 148 ovarian cancers with results from breast cancer tissue samples and the available patient data. This comparison uncovered interesting differences between the two tissue types. While around 25% of ovarian cancer samples also exhibited a high occurrence of the HER2/neu receptor (a known fact), a different signal molecule (CXCR4) was unaffected in the ovarian cancer tissue. However, breast cancer cells, which exhibit elevated levels of HER2/neu, also produce greater amounts of CXCR4 than healthy cells. The CXCR4 molecule has been linked to the formation of metastases and it is assumed that HER2/neu induces the formation of CXCR4 while simultaneously protecting the molecule against degradation caused by enzymes, thus enabling the cancer to become more aggressive (i.e. metastasising). The results from the Medical University of Vienna now show that the signalling effect produced by HER/2neu is not involved in ovarian cancer.

Molecular Diagnostics Optimise Therapy

Prof. Krainer on the significance of these results: "For almost ten years we have been able to identify hereditary breast cancer using molecular diagnostics and rely on monoclonal antibodies for therapy. The first antibody to be approved for use as a medicine blocks precisely the HER2/neu receptor, thus impeding the cancer’s growth. This is a perfect example of a tailor-made approach to therapy. Our work now reveals just how important it is to carry this differentiation further forward in the development of cancer therapies. After all, in the case of ovarian cancer cells, although the same monoclonal antibody fits this receptor, it has little effect. My laboratory is using findings such as these to create a basis for optimizing the treatment of cancer and to discover where therapies are going wrong. We are very grateful for the support we have received from the FWF, particularly since the potential – including the financial potential – that fundamental research offers for the health system seems not to have been fully recognized yet."

This study, supported by the FWF Austrian Science Fund, clearly demonstrates just how important results from fundamental research can be for state-of-the-art cancer therapy. Furthermore, studies such as this also enable health professionals to choose the optimum treatment for each individual patient from a vast range of therapies. After all, there is no one-size-fits-all treatment for cancer.

Till C. Jelitto | alfa
Further information:

Further reports about: CXCR4 HER2/neu breast cancer ovarian receptor therapies

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>